USP25

Across TCGA pan-cancer cohorts, USP25 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated USP25 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher USP25 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated USP25 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, UCEC, and KIRC are the cancer types where USP25 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	All	0.316	0.843	<.001	36	view →
UCEC	DFS	Median	All	0.967	0.821	.001	34	view →
KIRC	OS	Median	All	0.199	0.807	<.001	30	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

USP25–OV (OS)

Open the OV breakdown →